Send to

Choose Destination
Cancer Cell. 2011 Oct 18;20(4):420-3. doi: 10.1016/j.ccr.2011.10.004.

The spliceosome as an indicted conspirator in myeloid malignancies.

Author information

Human Oncology and Pathogenesis Program, Leukemia Service, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10065, USA.


Reports of whole-exome sequencing in myelodysplastic syndrome (MDS) patients by Yoshida et al. and Papaemmanuil et al. suggest spliceosome mutations have clinical relevance. Identifying the impact of these mutations on MDS pathogenesis holds promise for therapeutic modulation of mRNA splicing.

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center